UK’s life sciences sector continues to attract talent despite Brexit fear

26 Nov 2019

The largest area of growth has been within biotechnology companies, where job openings increased by 35%.

Despite the on-going political and economic turmoil, demand for professionals to work within the UK’s life sciences sector increased by 25% in 2019, according to data from the Association of Professional Staffing Companies (APSCo) and business intelligence specialist, Vacancysoft.

UK’s life sciences sector continues to attract talent despite Brexit fear

The research also revealed that, while pharmaceutical firms continue to provide the lion’s share of professional opportunities, the largest area of growth has been within biotechnology companies, where job openings increased by 35%. Demand for professionals in clinical research organisations was also high, rising by 25% year-on-year.

In terms of function, R&D remains the strongest area for hiring, with vacancies up by 31% since 2018. Demand for quality assurance specialists was also notable, rising by 28%. By specialist role, clinical researchers were noted as a fast growth profession, increasing by 25% within clinical research organisations and 10% across Big Pharma.

South East England is the most dominant region for hiring life sciences professionals, accounting for 37% of all vacancies in the UK in 2019. Since 2018, job openings in the region have increased by 22%. In London, vacancies rose by 30% over the same period and now account for 18% of total roles. While accounting for a smaller proportion of overall vacancies, the East Midlands, Yorkshire & the Humber, South West England and North East England all noted 50%+ year-on-year growth in demand for professionals to work in the sector.

Research organisation, Covance, is now the largest single hirer of life sciences professionals in the UK, with vacancies up by 111% year-on-year in 2019. PRA Health Sciences, Envigo and AstraZeneca are also major players, with vacancies at these firm increasing by 210%, 71% and 21%, respectively.

Ann Swain, Chief Executive of APSCo, commented: “The UK life sciences sector is the most productive in the G7, and it’s encouraging to see that the government is fully committed to supporting its growth and by default, jobs in the sector. There are ambitious plans in the pipeline - as outlined in Sir John Bell’s Life Sciences Industrial Strategy - which focus on developing cutting-edge technology and new innovations along with £1.2 billion of new investment that will further strengthen the UK as a world-leading science base.”

James Chaplin, CEO of Vacancysoft, added: “The life sciences sector in the UK continues to go from strength to strength, and is undoubtedly a critical part of the nation’s economic strength. It contributes over £70 billion a year to the economy and supports 240,000 jobs - with no signs of slowing down. It is also unsurprising to see that R&D continues to be one of the strongest areas for hiring, as the government has recently announced that it is committed to raising the intensity of R&D spend to reach 2.4% of GDP in the UK by 2027.”

Read More

Related news

FDA orders ranitidine withdrawal due to nitrosamine contamination risk

FDA orders ranitidine withdrawal due to nitrosamine contamination risk

2 Apr 2020

US drug regulator, the Food and Drug Administration has ordered the immediate withdrawal of all prescription and over-the-counter versions of heartburn drug, ranitidine – commonly known as Zantac – after concluding certain products may present an incre...

Read more 
China focused on meeting international API demand amid pandemic, say officials

China focused on meeting international API demand amid pandemic, say officials

1 Apr 2020

China is stepping up its efforts to produce and ship active pharmaceutical ingredients (APIs), with a focus on meeting international demand, particularly for those showing potential to treat the COVID-19 disease, according to Chinese officials Tuesday.

Read more 
CDMO Suven’s finished drug exports halted due to Indian COVID-19 lockdown

CDMO Suven’s finished drug exports halted due to Indian COVID-19 lockdown

25 Mar 2020

Indian contract development and manufacturing organisation, Suven Pharmaceuticals, has warned it cannot export finished products due to a shortage of raw materials following the country’s recent lockdown to fight the COVID-19 pandemic.

Read more 
2020 - a year for 'big answers' rather than 'big data'

2020 - a year for 'big answers' rather than 'big data'

7 Feb 2020

Zenith Technologies CEO, Joe Haugh, takes us through how the business has evolved this year, to better meet the needs of its customers, as well as the trends they see shaping the industry through 2020 and beyond.

Read more 
Inovio and Beijing Advaccine to advance vaccine against Coronavirus

Inovio and Beijing Advaccine to advance vaccine against Coronavirus

30 Jan 2020

Agreement will facilitate clinical trial translations in China.

Read more 
AstraZeneca embarks on $1bn zero carbon strategy

AstraZeneca embarks on $1bn zero carbon strategy

24 Jan 2020

The programme will include the launch of next-generation respiratory inhalers, which will use near-zero Global Warming Potential propellants.

Read more 
Diabetes diagnosis - now a matter of sweat and tears?

Diabetes diagnosis - now a matter of sweat and tears?

21 Jan 2020

No need to draw blood; researchers develop smart technology to diagnose diabetes and treat diabetic retinopathy.

Read more 
2019, the year that got serialization done!

2019, the year that got serialization done!

17 Dec 2019

The past 12 months have been busy as many companies fought to comply with serialization regulations.

Read more 
Edible barcodes - it's Tru!

Edible barcodes - it's Tru!

10 Dec 2019

Smart tags on pills set to improve supply chain security and patient adherence.

Read more 
US Pharmaceutical industry continues to shine according to CPhI 2019 Annual Report

US Pharmaceutical industry continues to shine according to CPhI 2019 Annual Report

9 Dec 2019

The US pharmaceutical industry continues to lead its global peers in terms of innovation and competitiveness, while still ranking high in overall growth potential despite its mature status, according to the results of a survey of 350 global pharmaceuti...

Read more